99% Savings - Buy Just @1 Rs X
Olvan Trio 40 Tablet is a commercial drug that is prescribed in the form of Tablet. Other than this, Olvan Trio 40 Tablet has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Olvan Trio 40 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. This information has been provided in detail in the dosage section.
Common side effects of Olvan Trio 40 Tablet include Upper respiratory tract infection, Loss of appetite, Gastric Irritation. Besides the aforementioned side effects, there are other adverse effects of Olvan Trio 40 Tablet as well, which are listed below. Such side effects of Olvan Trio 40 Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Olvan Trio 40 Tablet's effect during pregnancy is Mild and Mild while nursing. Further, the section on Olvan Trio 40 Tablet related warnings talks about Olvan Trio 40 Tablet's effects on the liver, heart and kidney.
Olvan Trio 40 Tablet is contraindicated in people with pre-existing medical conditions like Bradycardia (Slow Heart Rate), Low Blood Pressure (Hypotension), Low Blood Pressure (Hypotension) as it can result in adverse effects. Other conditions have been mentioned below in the Olvan Trio 40 Tablet contraindications section.
Besides this, Olvan Trio 40 Tablet may also have severe interaction with some medicines. See below for a complete list.
You should also be aware that Olvan Trio 40 Tablet is not safe while driving, and is not addiction.
Olvan Trio 40 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Olvan Trio 40 Tablet safe for pregnant women?
Pregnant women may get mild side effects from Olvan Trio.
Is the use of Olvan Trio 40 Tablet safe during breastfeeding?
Olvan Trio has been seen to have minimal side effects on breastfeeding women.
What is the effect of Olvan Trio 40 Tablet on the Kidneys?
Olvan Trio rarely affects the kidneys.
What is the effect of Olvan Trio 40 Tablet on the Liver?
Olvan Trio is rarely harmful for the liver.
What is the effect of Olvan Trio 40 Tablet on the Heart?
Side effects of Olvan Trio rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Olvan Trio 40 Tablet unless your doctor advises you to do so -
Is this Olvan Trio 40 Tablet habit forming or addictive?
Olvan Trio 40 Tablet does not cause addiction.
Interaction between Food and Olvan Trio 40 Tablet
Some foods when eaten with Olvan Trio 40 Tablet can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Olvan Trio 40 Tablet
Consult your doctor before consuming alcohol while taking Olvan Trio 40 Tablet as it can have severe side effects.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Benicar (olmesartan medoxomil)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Thalitone ® (chlorthalidone)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 583-584
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 446-448